Valuation : ANI Pharmaceuticals, Inc.

Market Cap 1.54B 1.33B 1.25B 1.14B 2.14B 146B 2.15B 14.78B 5.75B 74.4B 5.79B 5.66B 247B P/E 2026 *
14.7x
P/E 2027 * 13.2x
Enterprise Value 1.7B 1.46B 1.38B 1.25B 2.36B 161B 2.37B 16.27B 6.33B 81.87B 6.37B 6.23B 271B EV / Sales 2026 *
1.54x
EV / Sales 2027 * 1.2x
Free-Float
86.74%
Yield 2026 *
-
Yield 2027 * -
1 day-1.82%
1 week-4.93%
Current month-1.82%
1 month-9.24%
3 months-6.24%
6 months-2.68%
Current year-8.89%
1 week 71.56
Extreme 71.56
74.99
1 month 71.56
Extreme 71.56
83.21
Current year 70.15
Extreme 70.15
87.76
1 year 70.15
Extreme 70.15
99.5
3 years 48.2
Extreme 48.2
99.5
5 years 22.31
Extreme 22.31
99.5
10 years 22.31
Extreme 22.31
99.5
Manager TitleAgeSince
Chief Executive Officer 48 2020-09-07
Director of Finance/CFO 55 2016-05-05
Compliance Officer - 2022-02-23
Director TitleAgeSince
Chairman 62 2025-11-23
Director/Board Member 68 2020-08-05
Director/Board Member 66 2020-08-05
Date Insider Type Main position Quantity % Market Cap. Importance
8/25/26 Sell

Chief Executive Officer

-5,400 0.0235%
8/19/26 Free

Director

6,662 0.0290%
8/13/26 Sell

General Counsel

-500 0.0022%
Change 5-day change 1-year change 3-year change Capi.($)
-1.82%-4.93%-23.08%+11.37% 1.57B
+0.28%-5.97%+58.34%+108.22% 1,031B
+2.01%-0.71%+53.07%+68.99% 641B
+1.39%-2.18%+23.57%+75.43% 453B
-1.50%-7.04%+33.55%+33.94% 349B
+6.25%+2.04%+28.97%+46.57% 290B
-0.07%-4.12%+0.95%+11.79% 252B
+1.92%-0.93%+52.28%+70.67% 232B
+0.51%-4.52%-19.50%-54.83% 201B
+2.45%+0.77%+32.71%+95.59% 181B
Average +1.27%-2.74%+24.09%+46.77% 363.13B
Weighted average by Cap. +1.60%-3.40%+38.36%+66.37%

Financials

2026 *2027 *
Net sales 1.1B 951M 895M 815M 1.53B 105B 1.54B 10.58B 4.12B 53.24B 4.14B 4.05B 177B 1.23B 1.06B 998M 909M 1.71B 117B 1.72B 11.8B 4.59B 59.37B 4.62B 4.52B 197B
Net income 113M 97.6M 91.81M 83.64M 157M 10.74B 158M 1.09B 422M 5.46B 425M 416M 18.11B 125M 108M 102M 92.62M 174M 11.89B 175M 1.2B 468M 6.05B 470M 460M 20.06B
Net Debt 155M 133M 126M 114M 215M 14.68B 216M 1.48B 577M 7.47B 581M 568M 24.76B -69.84M -60.25M -56.67M -51.63M -97.09M -6.63B -97.61M -670M -261M -3.37B -262M -257M -11.18B
Logo ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units, Rare Disease and Brands. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel and ILUVIEN. The Brands unit includes a portfolio of over 20 branded products that are principally sold in genericized markets. Its Generics and Other segment consists of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Employees
970
Date Price Change Volume
26-09-01 US$71.92 -1.82% 580,536
26-08-31 US$73.25 +0.58% 340,549
26-08-28 US$72.83 -0.93% 360,970
26-08-27 US$73.51 -1.41% 316,607
26-08-26 US$74.56 -1.44% 412,007
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
71.92USD
Average target price
108.38USD
Spread / Average Target
+50.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANIP Stock